Agilon Health shares jump 10.84% intraday after Leerink upgrades long-term earnings forecasts.

Agilon Health surged 10.84% in intraday trading following a positive analyst upgrade from Leerink Partners, which raised medium- to long-range earnings forecasts for FY2026–FY2029 and adjusted near-term estimates. This signaled improved confidence in Agilon’s future profitability trajectory despite ongoing challenges, including a NYSE non-compliance notice over its $1 minimum price standard, multiple analyst downgrades, and active securities investigations. The upgrade offset near-term bearish catalysts, such as liquidity risks and litigation pressures, temporarily boosting investor sentiment. The move reflects a conditional optimism tied to potential execution improvements and margin recovery, even as structural risks remain unresolved.